Eledon Total Current Assets vs Total Current Liabilities Analysis

ELDN Stock

USD 4.01 0.06 1.47%

Eledon Pharmaceuticals financial indicator trend analysis is much more than just examining Eledon Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eledon Pharmaceuticals is a good investment. Please check the relationship between Eledon Pharmaceuticals Total Current Assets and its Total Current Liabilities accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.

Total Current Assets vs Total Current Liabilities

Total Current Assets vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eledon Pharmaceuticals Total Current Assets account and Total Current Liabilities. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Eledon Pharmaceuticals' Total Current Assets and Total Current Liabilities is 0.57. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Eledon Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Eledon Pharmaceuticals' Total Current Assets and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Eledon Pharmaceuticals are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Total Current Assets i.e., Eledon Pharmaceuticals' Total Current Assets and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.57

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Total Current Liabilities

Total Current Liabilities is an item on Eledon Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Eledon Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Eledon Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eledon Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.Eledon Pharmaceuticals reported last year Tax Provision of (579,000). As of the 25th of November 2024, Enterprise Value Over EBITDA is likely to grow to 0.25, while Selling General Administrative is likely to drop about 10.4 M.

Eledon Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock Total Equity	Common Stock	Short Term Investments	Short Long Term Debt Total	Net Tangible Assets	Current Deferred Revenue	Other Assets
Total Assets		0.26	0.49	0.94	0.53	-0.76	-0.44	0.66	0.76	0.85	-0.03	0.91	0.48	-0.31	0.6	0.8	-0.28	0.53	0.92	-0.15	-0.04	-0.18	-0.41	0.79	0.28	0.59
Other Current Liab	0.26		0.76	0.22	0.44	-0.18	-0.27	0.43	0.17	0.06	-0.21	0.4	0.24	-0.05	0.43	0.22	0.0	0.44	0.41	0.09	0.13	0.39	0.06	0.1	0.15	-0.2
Total Current Liabilities	0.49	0.76		0.51	0.75	-0.32	-0.65	0.75	0.32	0.3	-0.32	0.56	0.44	-0.33	0.72	0.66	-0.27	0.75	0.57	0.14	0.15	0.06	-0.01	0.35	0.15	-0.13
Total Stockholder Equity	0.94	0.22	0.51		0.56	-0.75	-0.41	0.68	0.75	0.76	0.18	0.89	0.41	-0.61	0.58	0.82	-0.58	0.56	0.89	-0.29	-0.23	-0.4	-0.51	0.73	0.17	0.56
Property Plant And Equipment Net	0.53	0.44	0.75	0.56		-0.22	-0.58	0.78	0.23	0.53	-0.05	0.39	0.58	-0.37	0.63	0.74	-0.33	1.0	0.41	-0.18	-0.15	-0.29	-0.38	0.56	0.16	-0.08
Net Debt	-0.76	-0.18	-0.32	-0.75	-0.22		-0.05	-0.47	-1.0	-0.38	0.01	-0.87	0.08	0.39	-0.1	-0.38	0.37	-0.22	-0.86	-0.08	0.06	0.25	0.08	-0.33	0.31	-0.59
Retained Earnings	-0.44	-0.27	-0.65	-0.41	-0.58	-0.05		-0.46	0.04	-0.57	0.28	-0.34	-0.83	0.08	-0.92	-0.77	0.03	-0.58	-0.36	0.06	-0.18	-0.06	0.25	-0.63	-0.71	0.1
Accounts Payable	0.66	0.43	0.75	0.68	0.78	-0.47	-0.46		0.47	0.6	-0.14	0.56	0.49	-0.38	0.54	0.71	-0.33	0.78	0.57	-0.12	-0.15	-0.25	-0.33	0.66	0.06	0.23
Cash	0.76	0.17	0.32	0.75	0.23	-1.0	0.04	0.47		0.38	-0.01	0.87	-0.08	-0.39	0.11	0.39	-0.38	0.23	0.86	0.08	-0.05	-0.26	-0.08	0.33	-0.32	0.58
Non Current Assets Total	0.85	0.06	0.3	0.76	0.53	-0.38	-0.57	0.6	0.38		0.07	0.61	0.77	-0.09	0.68	0.77	-0.07	0.53	0.62	-0.38	-0.21	-0.22	-0.63	0.96	0.54	0.48
Non Currrent Assets Other	-0.03	-0.21	-0.32	0.18	-0.05	0.01	0.28	-0.14	-0.01	0.07		-0.11	-0.04	-0.51	-0.2	-0.05	-0.55	-0.05	-0.11	-0.88	-0.88	-0.7	-0.73	0.14	-0.08	0.12
Cash And Short Term Investments	0.91	0.4	0.56	0.89	0.39	-0.87	-0.34	0.56	0.87	0.61	-0.11		0.27	-0.36	0.52	0.64	-0.32	0.39	1.0	0.05	0.05	-0.07	-0.17	0.55	0.09	0.54
Common Stock Shares Outstanding	0.48	0.24	0.44	0.41	0.58	0.08	-0.83	0.49	-0.08	0.77	-0.04	0.27		0.08	0.86	0.65	0.11	0.58	0.29	-0.37	-0.11	0.02	-0.53	0.8	0.8	-0.11
Non Current Liabilities Total	-0.31	-0.05	-0.33	-0.61	-0.37	0.39	0.08	-0.38	-0.39	-0.09	-0.51	-0.36	0.08		-0.14	-0.43	1.0	-0.37	-0.37	0.38	0.46	0.68	0.41	-0.15	0.24	-0.19
Other Current Assets	0.6	0.43	0.72	0.58	0.63	-0.1	-0.92	0.54	0.11	0.68	-0.2	0.52	0.86	-0.14		0.78	-0.09	0.63	0.55	-0.1	0.12	0.11	-0.28	0.67	0.7	-0.08
Other Stockholder Equity	0.8	0.22	0.66	0.82	0.74	-0.38	-0.77	0.71	0.39	0.77	-0.05	0.64	0.65	-0.43	0.78		-0.39	0.74	0.66	-0.22	-0.03	-0.29	-0.48	0.79	0.45	0.33
Total Liab	-0.28	0.0	-0.27	-0.58	-0.33	0.37	0.03	-0.33	-0.38	-0.07	-0.55	-0.32	0.11	1.0	-0.09	-0.39		-0.33	-0.33	0.4	0.49	0.7	0.42	-0.13	0.26	-0.2
Property Plant And Equipment Gross	0.53	0.44	0.75	0.56	1.0	-0.22	-0.58	0.78	0.23	0.53	-0.05	0.39	0.58	-0.37	0.63	0.74	-0.33		0.41	-0.18	-0.15	-0.29	-0.38	0.56	0.16	-0.08
Total Current Assets	0.92	0.41	0.57	0.89	0.41	-0.86	-0.36	0.57	0.86	0.62	-0.11	1.0	0.29	-0.37	0.55	0.66	-0.33	0.41		0.03	0.05	-0.07	-0.18	0.57	0.11	0.53
Common Stock Total Equity	-0.15	0.09	0.14	-0.29	-0.18	-0.08	0.06	-0.12	0.08	-0.38	-0.88	0.05	-0.37	0.38	-0.1	-0.22	0.4	-0.18	0.03		0.88	0.62	0.93	-0.5	-0.27	-0.14
Common Stock	-0.04	0.13	0.15	-0.23	-0.15	0.06	-0.18	-0.15	-0.05	-0.21	-0.88	0.05	-0.11	0.46	0.12	-0.03	0.49	-0.15	0.05	0.88		0.79	0.78	-0.33	0.17	-0.16
Short Term Investments	-0.18	0.39	0.06	-0.4	-0.29	0.25	-0.06	-0.25	-0.26	-0.22	-0.7	-0.07	0.02	0.68	0.11	-0.29	0.7	-0.29	-0.07	0.62	0.79		0.65	-0.31	0.34	-0.31
Short Long Term Debt Total	-0.41	0.06	-0.01	-0.51	-0.38	0.08	0.25	-0.33	-0.08	-0.63	-0.73	-0.17	-0.53	0.41	-0.28	-0.48	0.42	-0.38	-0.18	0.93	0.78	0.65		-0.74	-0.36	-0.33
Net Tangible Assets	0.79	0.1	0.35	0.73	0.56	-0.33	-0.63	0.66	0.33	0.96	0.14	0.55	0.8	-0.15	0.67	0.79	-0.13	0.56	0.57	-0.5	-0.33	-0.31	-0.74		0.54	0.48
Current Deferred Revenue	0.28	0.15	0.15	0.17	0.16	0.31	-0.71	0.06	-0.32	0.54	-0.08	0.09	0.8	0.24	0.7	0.45	0.26	0.16	0.11	-0.27	0.17	0.34	-0.36	0.54		-0.09
Other Assets	0.59	-0.2	-0.13	0.56	-0.08	-0.59	0.1	0.23	0.58	0.48	0.12	0.54	-0.11	-0.19	-0.08	0.33	-0.2	-0.08	0.53	-0.14	-0.16	-0.31	-0.33	0.48	-0.09

Click cells to compare fundamentals

Eledon Pharmaceuticals Account Relationship Matchups

Eledon Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	10.9M	197.2M	170.5M	92.8M	125.9M	81.1M
Other Current Liab	813K	829K	1.9M	3.5M	2.5M	2.1M
Total Current Liabilities	1.3M	2.5M	4.4M	6.5M	3.9M	3.7M
Total Stockholder Equity	9.5M	190.6M	164.0M	84.2M	83.4M	60.7M
Property Plant And Equipment Net	321K	138K	768K	739K	365K	278.2K
Net Debt	(8.5M)	(114.1M)	(84.1M)	(55.7M)	(4.2M)	(4.4M)
Retained Earnings	(57.6M)	(80.4M)	(114.9M)	(202.9M)	(243.2M)	(231.0M)
Accounts Payable	329K	1.4M	1.8M	2.2M	967K	1.0M
Cash	8.8M	114.2M	84.8M	56.4M	4.6M	4.4M
Non Current Assets Total	960K	81.6M	82.2M	33.3M	69.8M	73.3M
Non Currrent Assets Other	639K	383K	400K	150K	186K	309.2K
Cash And Short Term Investments	8.8M	114.2M	84.8M	56.4M	51.1M	53.7M
Common Stock Shares Outstanding	655.5K	1.5M	14.8M	14.3M	24.6M	25.9M
Liabilities And Stockholders Equity	10.9M	197.2M	170.5M	92.8M	125.9M	81.1M
Non Current Liabilities Total	144K	4.1M	2.2M	2.1M	38.6M	40.5M
Other Current Assets	54K	1.3M	3.5M	3.1M	5.0M	5.3M
Other Stockholder Equity	67.0M	271.0M	278.9M	287.0M	326.6M	166.9M
Total Liab	1.5M	6.6M	6.6M	8.6M	42.5M	44.6M
Property Plant And Equipment Gross	321K	138K	768K	739K	365K	278.2K
Total Current Assets	10.0M	115.6M	88.3M	59.5M	56.1M	56.0M
Common Stock Total Equity	7K	9K	13K	15K	13.5K	12.8K
Common Stock	9K	13K	15K	14K	24K	13.1K
Net Tangible Assets	12.6M	9.5M	109.6M	83.0M	95.4M	100.2M
Property Plant Equipment	14K	321K	138K	768K	883.2K	927.4K
Net Invested Capital	9.5M	190.6M	164.0M	84.2M	83.4M	88.9M
Net Working Capital	8.6M	113.1M	83.9M	53.0M	52.2M	53.5M

Pair Trading with Eledon Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eledon Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eledon Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Eledon Stock

0.83	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.8	MTEM	Molecular Templates	Pair Corr
0.75	TPST	Tempest Therapeutics	Pair Corr
0.74	ME	23Andme Holding	Pair Corr
0.72	NKTX	Nkarta Inc	Pair Corr

The ability to find closely correlated positions to Eledon Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eledon Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eledon Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eledon Pharmaceuticals to buy it.

The correlation of Eledon Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eledon Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eledon Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Eledon Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Eledon Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eledon Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eledon Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eledon Pharmaceuticals Stock:

How To Invest In Eledon

Details

Is Eledon Stock a good investment?

Details

What is Eledon Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

0.73

Return On Assets

(0.33)

Return On Equity

(0.25)

The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Eledon Total Current Assets vs Total Current Liabilities Analysis

Total Current Assets vs Total Current Liabilities

Total Current Assets vs Total Current Liabilities Correlation Analysis

Correlation Coefficient

Total Current Assets

Total Current Liabilities

Eledon Pharmaceuticals fundamental ratios Correlations

Eledon Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Eledon Pharmaceuticals fundamental ratios Accounts

Pair Trading with Eledon Pharmaceuticals

Moving against Eledon Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 1.0	Non Current Liabilities Total
Net Tangible Assets	+ 0.96	Non Current Assets Total
Total Stockholder Equity	+ 0.94	Total Assets
Short Long Term Debt Total	+ 0.93	Common Stock Total Equity

Cash	- 1.0	Net Debt
Other Current Assets	- 0.92	Retained Earnings
Common Stock	- 0.88	Non Currrent Assets Other
Common Stock Total Equity	- 0.88	Non Currrent Assets Other
Cash And Short Term Investments	- 0.87	Net Debt
Total Current Assets	- 0.86	Net Debt